Company Continues to Deepen Executive Bench with Life Science Industry Veterans TORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for ...
“Raising Capital for Psychedelic Endeavors” Panel Part of Conference’s Psychedelic Business Forum TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel serotonergic psychedelic drug development committed to ...
TORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc . (TSX: REUN, NASDAQ: REUN) (" Reunion " or the “ Company ”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor ...
TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced that management will ...
TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion " or the “ Company ”) today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders (the “ Meeting ”)...
Bringing a 20-Year Track Record of Success in the Biopharma Industry, Mayes Succeeds Joseph del Moral, Who Assumes the Role of Chairman TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug ...
TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate ...
TORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, today announced it has scheduled ...
Aug. 29, 2022 -- Completed corporate reorganization on August 11, 2022 separating the drug development (“Reunion Neuroscience Inc.” or “Reunion”) and healthcare and wellness (“Field Trip Health & Wellness” or “Field Trip”) divisions into two separate public companies (the “Spinout Transaction”)...
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the " Company " or “ Reunion ”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce ...